The Slice is Right

The Slice is Right

Kalorama Information is pleased to announce that you can now buy slices of our industry-leading market research reports.


Germany Becomes Biosimilar HotSpot

Germany Becomes Biosimilar HotSpot

A more efficient regulatory pathway, large market and pricing pressures has made Germany the lead market for biosimilars. These are the close "generic like" replicas of biological drugs. Kalorama Information's new report details markets by country and finds the leading EU market has an advantage on other world pharmaceutical markets.


For Major Biopharma Products, Competition is Coming

For Major Biopharma Products, Competition is Coming

Biosimilars- close replicas of profitable biopharmaceutical drugs, are arriving to the U.S. market. This according to Kalorama Information's new market research study. There are dozens of companies developing similar biotherapeutics. And although they've been slow to develop in the U.S. market, there's more world development and signs of change.

  • by Bruce Carlson
  • November 15 2017


Oncology Remains Most Active, Highest-Growth Area for LDTs

Oncology Remains Most Active, Highest-Growth Area for LDTs

There will be a robust market for LDTs because there aren't enough commercial test solutions for the clinical needs of labs. So predicts a report from Kalorama.


Letting Robots Do the Menial Work So Labs Don't Have To

Reducing the time wasted taking on preparation and maintenance steps will give clinicians and technicians more time to devote to the more important task of analyzing the results, getting more actual research done, and moving on to the next big study sooner. In this article, based on Kalorama's Robotic Laboratory Automation report, we discuss these steps.

  • by Bruce Carlson
  • October 24 2017


Four Trends in Clinical Chemistry

Four Trends in Clinical Chemistry

Watch these 4 important trends with in the largest and most basic category of IVD testing, from Kalorama Information's complete study of the market.


Five Reasons to Be Bullish on Medical Devices

Five Reasons to Be Bullish on Medical Devices

Kalorama Information has increased our projection of the growth rate for the overall medical device market. From pharmaceutical replacement to advanced pricing, This article summarizes the reasons why, though it's not all upside, and there is greater explanation and data in our 2017 global medical device report.

  • by Aaron Hackle
  • October 6 2017


CMS's Deep PAMA Cuts Surprise Industry

CMS's Deep PAMA Cuts Surprise Industry

PAMA's price cuts were even higher than Kalorama had predicted in June, but some advanced testmakers got good news.

  • by Bruce Carlson
  • September 29 2017


Kalorama’s Knowledge Center Now Available to Government Agencies via Carahsoft

Kalorama’s Knowledge Center Now Available to Government Agencies via Carahsoft

Although Kalorama Information reports find use among executives engaging in business planning or considering competitive actions or product launches, they can also be useful for government agencies.

  • by Bruce Carlson
  • September 26 2017


Malignant Mesothelioma: Another Job for Liquid Biopsy

Malignant Mesothelioma: Another Job for Liquid Biopsy

Mesothelioma treatment is imperiled by late detection. New non-invasive liquid biopsy approaches are showing promise, as this article demonstrates.